GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BioTelemetry Inc (NAS:BEAT) » Definitions » EV-to-EBIT

BioTelemetry (BioTelemetry) EV-to-EBIT : 66.86 (As of Apr. 26, 2024)


View and export this data going back to 2008. Start your Free Trial

What is BioTelemetry EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, BioTelemetry's Enterprise Value is $2,543.2 Mil. BioTelemetry's EBIT for the trailing twelve months (TTM) ended in Sep. 2020 was $38.0 Mil. Therefore, BioTelemetry's EV-to-EBIT for today is 66.86.

The historical rank and industry rank for BioTelemetry's EV-to-EBIT or its related term are showing as below:

BEAT' s EV-to-EBIT Range Over the Past 10 Years
Min: 27.42   Med: 44.28   Max: 971.84
Current: 66.86

During the past 13 years, the highest EV-to-EBIT of BioTelemetry was 971.84. The lowest was 27.42. And the median was 44.28.

BEAT's EV-to-EBIT is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 20.23 vs BEAT: 66.86

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. BioTelemetry's Enterprise Value for the quarter that ended in Sep. 2020 was $1,635.8 Mil. BioTelemetry's EBIT for the trailing twelve months (TTM) ended in Sep. 2020 was $38.0 Mil. BioTelemetry's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2020 was 2.33%.


BioTelemetry EV-to-EBIT Historical Data

The historical data trend for BioTelemetry's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioTelemetry EV-to-EBIT Chart

BioTelemetry Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.27 36.03 -207.01 41.21 29.91

BioTelemetry Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.48 29.91 36.65 38.42 40.23

Competitive Comparison of BioTelemetry's EV-to-EBIT

For the Diagnostics & Research subindustry, BioTelemetry's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioTelemetry's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BioTelemetry's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BioTelemetry's EV-to-EBIT falls into.



BioTelemetry EV-to-EBIT Calculation

BioTelemetry's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=2543.239/38.037
=66.86

BioTelemetry's current Enterprise Value is $2,543.2 Mil.
BioTelemetry's EBIT for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $38.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioTelemetry  (NAS:BEAT) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

BioTelemetry's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2020 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2020 ) =EBIT / Enterprise Value (Q: Sep. 2020 )
=38.037/1635.75122
=2.33 %

BioTelemetry's Enterprise Value for the quarter that ended in Sep. 2020 was $1,635.8 Mil.
BioTelemetry's EBIT for the trailing twelve months (TTM) ended in Sep. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $38.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioTelemetry EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of BioTelemetry's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


BioTelemetry (BioTelemetry) Business Description

Traded in Other Exchanges
N/A
Address
1000 Cedar Hollow Road, Suite 102, Malvern, PA, USA, 19355
BioTelemetry Inc provides monitoring services and digital population health management for healthcare providers, medical device manufacturing, and centralized core laboratory services for clinical research. It operates under healthcare, technology, and research segments. The Healthcare segment is focused on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders. The Research segment is engaged in central core laboratory services providing cardiac monitoring, imaging services, scientific consulting and data management services for drug and medical device trials and the Technology segment, focuses on the development, manufacturing, testing, and marketing of cardiovascular and blood glucose monitoring devices to medical companies, clinics and hospitals.
Executives
Kirk E Gorman director 367 SOUTH GULPH ROAD, KING PRUSSIA PA 19406
Stephen Rietiker director C/O BIOTELEMETRY, INC., 1000 CEDAR HOLLOW RD. SUITE 102, MALVERN PA 19355
Tiffany Olson director C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Joseph A. Frick director ONE COMMERCE SQUARE 2005 MARKET ST., SUITE 3300 19103 PR 19073
Laura N. Dietch director 1000 CEDAR HOLLOW RD. SUITE 102 MALVERN PA 19355
Anthony James Conti director 76 GOLFVIEW DRIVE, IVYLAND PA 18974
Rebecca W Rimel director 345 PARK AVENUE, NEW YORK NY 10154
Robert J. Rubin director 7901 SPRINGER ROAD, BETHESDA MD 20817
Hill Colin director 196 BROADWAY CAMBRIDGE MA 02139
Andrei G Stoica officer: SVP & CTO 1000 CEDAR HOLLOW ROAD, MALVERN PA 19355
Joseph H Capper director, officer: President & CEO BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355
Manish Wadhwa officer: SVP & CMO 1000 CEDAR HOLLOW ROAD MALVERN PA 19355
Fred Broadway officer: President BioTel Heart BIOTELEMETRY, INC. 1000 CEDAR HOLLOW ROAD, #102 MALVERN PA 19355
Daniel Wisniewski officer: SVP, Technical Operations BIOTELEMETRY, INC. 1000 CEDAR HOLLOW ROAD, #102 MALVERN PA 19355
Heather C Getz officer: EVP, CFO & CAO BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355